Phathom Pharmaceuticals, Inc. (PHAT)
$7.00-1.82%Close
SELLCRISIS · day 25
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $558M
- Beta
- 0.50
- P/E (TTM)
- -5.47
- Short % float
- 15.71%
- Days to cover
- 7.4
- SI change
- -0.5%
- 1W
- +3.24%
- 1M
- -19.35%
- vs SPY 1W
- +3.38%
- vs SPY 1M
- -21.86%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on PHAT?
- LOPJLB’s latest quantitative signal on Phathom Pharmaceuticals, Inc. (PHAT) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is PHAT in?
- Phathom Pharmaceuticals, Inc. (PHAT) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Phathom Pharmaceuticals, Inc. (PHAT) do?
- Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, E…